Severance

12 Months Ended

Dec. 31, 2022

Restructuring And Related Activities [Abstract]

Severance

21. SEVERANCE

On April 8, 2020, the Company took action to reduce expenses through a reduction in force (“RIF”). As part of this action the Company terminated 95 employees who received separation benefits upon their termination. During the second quarter of 2020, the Company recorded a separation-related charge for the RIF equal to the fair value of the terminated employees benefits as of the communication date in the amount of $2.1 million. This amount was paid out during the quarter with the final payoff occurring on June 15, 2020.

The Company entered into transition agreements outlining the separation with its former chief executive officer in March 2020, the vice president of medical operations in September 2020, and the chief commercial officer, vice president of commercial access and director of medical operations in December 2020, the VP of sales and five business development managers in January 2021, the director of strategic clinical development in February 2021, and the vice president of marketing in August 2021 and vice president of marketing in December 2022. In connection with these agreements, the Company recorded $0.6 million and $0.5 million of charges in salary, payroll tax and bonus expenses for the years ended December 31, 2022 and 2021, respectively. For the year ended December 31, 2022 and 2021, $0.5 million and $1.3 million of termination benefits were paid associated with the termination of the employees and charged against this liability. As of December 31, 2022 and December 31, 2021, $0.3 million and $0.1 million, respectively, remain in accrued liabilities for the unpaid portion of the separation benefits.